Incannex engages fortrea to manage its fda ind opening phase 2/3 clinical trial investigating ihl-42x for treatment of obstructive sleep apnoea

Highlights: incannex has engaged fortrea as the contract research organisation (‘cro') to manage the ind opening phase 2/3 clinical trial investigating ihl-42x for treatment of osa. the phase 2/3 clinical trial will assess the safety and efficacy of ihl-42x in people with osa who are intolerant, non-compliant, or naÏve to continuous positive airway pressure (‘cpap').
IXHL Ratings Summary
IXHL Quant Ranking